Revvity, Inc. (RVTY) 10-Year Financial Performance & Capital Metrics

RVTY • • Industrial / General

HealthcareDiagnostics & ResearchLife Sciences Instrumentation & ToolsLaboratory Equipment & Consumables

AboutRevvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.Show more

Revenue $2.76B +0.2%
EBITDA $838M +0.9%
Net Income $296M +349.9%
EPS (Diluted) 2.41 +353.9%
Gross Margin 48.01% -0.1%
EBITDA Margin 30.43% +0.7%
Operating Margin 14.9% +2.6%
Net Margin 10.74% +349.5%
ROE 3.81% +345.3%
ROIC 2.95% +11.1%
Debt/Equity 0.43 -16.0%
Interest Coverage 4.26 +5.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓FCF machine: 19.7% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 13.5%

✗Weaknesses

✗Weak 3Y average ROE of 3.4%
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y2.1%

5Y-0.91%

3Y-10.38%

TTM3.37%

Profit (Net Income) CAGR

10Y6.47%

5Y5.39%

3Y-32.06%

TTM-21.47%

EPS CAGR

10Y5.66%

5Y3.38%

3Y-33.2%

TTM-18.95%

ROCE

10Y Avg8.02%

5Y Avg8.56%

3Y Avg4.2%

Latest3.44%

Peer Comparison

Laboratory Equipment & Consumables

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
QGENQiagen N.V.	9.97B	48.38	127.32	0.66%	19.58%	11.11%	5.08%	0.40
RVTYRevvity, Inc.	13.08B	115.33	47.85	0.16%	8.47%	3.23%	4.14%	0.43
DHRDanaher Corporation	169.45B	239.89	45.35	-0.06%	14.43%	6.86%	3.13%	0.35
TMOThermo Fisher Scientific Inc.	234.69B	624.65	37.79	0.05%	15.02%	12.84%	3.1%	0.66
WATWaters Corporation	23.5B	394.59	36.84	0.07%	20.89%	27.84%	2.64%	0.93
MTDMettler-Toledo International Inc.	30.57B	1496.61	36.80	2.22%	21.2%		2.83%
AAgilent Technologies, Inc.	41.06B	144.83	31.69	6.73%	18.75%	19.33%	2.81%	0.50
TWSTTwist Bioscience Corporation	2.53B	41.27	-31.75	20.32%	-23.51%	-17.81%		0.16

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	2.1B	2.12B	2.26B	2.78B	2.88B	3.78B	3.83B	3.31B	2.75B	2.76B
Revenue Growth %	-0.06%	0.01%	0.07%	0.23%	0.04%	0.31%	0.01%	-0.13%	-0.17%	0%
Cost of Goods Sold+	1.17B	1.14B	1.23B	1.53B	1.59B	1.79B	1.55B	1.55B	1.43B	1.43B
COGS % of Revenue	0.56%	0.54%	0.54%	0.55%	0.55%	0.47%	0.4%	0.47%	0.52%	0.52%
Gross Profit+	930.03M	972.25M	1.03B	1.25B	1.29B	1.99B	2.28B	1.76B	1.32B	1.32B
Gross Margin %	0.44%	0.46%	0.46%	0.45%	0.45%	0.53%	0.6%	0.53%	0.48%	0.48%
Gross Profit Growth %	-0.04%	0.05%	0.06%	0.22%	0.03%	0.54%	0.15%	-0.23%	-0.25%	0%
Operating Expenses+	663.24M	666.58M	724.72M	880.27M	887.57M	970.72M	941.95M	979.61M	922.7M	912.14M
OpEx % of Revenue	0.32%	0.32%	0.32%	0.32%	0.31%	0.26%	0.25%	0.3%	0.34%	0.33%
Selling, General & Admin	551.2M	542.8M	585.56M	694.17M	698.24M	765.33M	741.61M	757.99M	706.12M	715.3M
SG&A % of Revenue	0.26%	0.26%	0.26%	0.25%	0.24%	0.2%	0.19%	0.23%	0.26%	0.26%
Research & Development	112.04M	123.78M	139.16M	186.1M	189.34M	205.39M	200.34M	221.62M	216.58M	196.84M
R&D % of Revenue	0.05%	0.06%	0.06%	0.07%	0.07%	0.05%	0.05%	0.07%	0.08%	0.07%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	266.79M	305.67M	304.63M	370.97M	405.48M	1.02B	1.34B	781.12M	399.49M	410.52M
Operating Margin %	0.13%	0.14%	0.13%	0.13%	0.14%	0.27%	0.35%	0.24%	0.15%	0.15%
Operating Income Growth %	0.16%	0.15%	-0%	0.22%	0.09%	1.52%	0.31%	-0.42%	-0.49%	0.03%
EBITDA+	372.16M	405.64M	409.63M	551.56M	619.51M	1.27B	1.65B	1.21B	831.26M	838.37M
EBITDA Margin %	0.18%	0.19%	0.18%	0.2%	0.21%	0.33%	0.43%	0.36%	0.3%	0.3%
EBITDA Growth %	0.07%	0.09%	0.01%	0.35%	0.12%	1.04%	0.3%	-0.27%	-0.31%	0.01%
D&A (Non-Cash Add-back)	105.36M	99.97M	105M	180.59M	214.03M	246.51M	311.44M	427M	431.77M	427.85M
EBIT	246.8M	285.6M	340.66M	324.66M	300.77M	956.08M	1.31B	755.79M	281.79M	412.4M
Net Interest Income+	-37.32M	-40.83M	-41.37M	-65.83M	-62.13M	-48.7M	-99.89M	-100.37M	-26.68M	-23.09M
Interest Income	673K	702K	2.57M	1.14M	1.5M	1.01M	2.24M	3.59M	72.13M	73.19M
Interest Expense	38M	41.53M	43.94M	66.98M	63.63M	49.71M	102.13M	103.95M	98.81M	96.28M
Other Income/Expense	-57.98M	-61.6M	-7.92M	-113.28M	-168.34M	-113.43M	-136.42M	-129.28M	-216.51M	-94.39M
Pretax Income+	208.81M	244.07M	296.72M	257.68M	237.14M	906.36M	1.2B	651.84M	182.98M	316.13M
Pretax Margin %	0.1%	0.12%	0.13%	0.09%	0.08%	0.24%	0.31%	0.2%	0.07%	0.11%
Income Tax+	20.02M	28.36M	139.83M	20.21M	9.39M	178.27M	314.15M	139.16M	3.47M	33.05M
Effective Tax Rate %	1.02%	0.96%	0.38%	0.93%	0.96%	0.8%	0.78%	0.87%	-0.65%	0.94%
Net Income+	212.45M	233.68M	113.02M	238.79M	227.56M	728.1M	943.16M	569.18M	-118.38M	295.83M
Net Margin %	0.1%	0.11%	0.05%	0.09%	0.08%	0.19%	0.25%	0.17%	-0.04%	0.11%
Net Income Growth %	0.34%	0.1%	-0.52%	1.11%	-0.05%	2.2%	0.3%	-0.4%	-1.21%	3.5%
Net Income (Continuing)	188.78M	215.71M	156.89M	237.47M	227.75M	728.1M	889.44M	512.68M	179.5M	283.07M
Discontinued Operations	23.67M	17.97M	-43.87M	1.31M	-195K	0	53.72M	56.5M	-297.88M	12.76M
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.87	2.12	1.02	2.14	2.04	6.49	8.08	4.50	-0.95	2.41
EPS Growth %	0.35%	0.13%	-0.52%	1.1%	-0.05%	2.18%	0.24%	-0.44%	-1.21%	3.54%
EPS (Basic)	1.89	2.13	1.03	2.16	2.05	6.53	8.12	4.51	-0.95	2.41
Diluted Shares Outstanding	113.31M	110.31M	110.86M	111.53M	111.5M	112.08M	116.67M	126.43M	124.81M	122.82M
Basic Shares Outstanding	112.51M	109.48M	109.86M	110.56M	110.83M	111.51M	116.17M	126.16M	124.7M	122.76M
Dividend Payout Ratio	0.15%	0.13%	0.27%	0.13%	0.14%	0.04%	0.03%	0.06%	-	0.12%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.03B	1.19B	1.2B	1.23B	1.37B	2.24B	2.44B	3.29B	3B	2.35B
Cash & Short-Term Investments	237.93M	359.26M	202.13M	163.11M	191.88M	402.04M	603.32M	454.36M	1.6B	1.16B
Cash Only	237.93M	359.26M	202.13M	163.11M	191.88M	402.04M	603.32M	454.36M	913.16M	1.16B
Short-Term Investments	0	0	0	0	0	0	0	0	689.92M	0
Accounts Receivable	415.06M	425.59M	552.3M	632.67M	725.18M	1.16B	707.94M	612.78M	632.81M	632.4M
Days Sales Outstanding	71.98	73.43	89.32	83.13	91.79	111.46	67.51	67.54	83.97	83.78
Inventory	259.49M	246.85M	351.68M	338.35M	356.94M	514.57M	425.89M	405.46M	428.06M	367.59M
Days Inventory Outstanding	80.62	78.81	104.56	80.89	81.91	104.8	100.56	95.41	109.38	93.67
Other Current Assets	120.68M	158.23M	93.84M	100.51M	100.38M	167.21M	703.63M	1.82B	337.14M	186.22M
Total Non-Current Assets+	3.13B	3.09B	4.89B	4.74B	5.16B	5.72B	12.56B	10.84B	10.56B	10.04B
Property, Plant & Equipment	137.56M	145.49M	298.07M	318.59M	485.5M	575.54M	649.57M	671.3M	664.74M	649.93M
Fixed Asset Turnover	15.30x	14.54x	7.57x	8.72x	5.94x	6.57x	5.89x	4.93x	4.14x	4.24x
Goodwill	2.24B	2.25B	3B	2.95B	3.11B	3.45B	6.63B	6.48B	6.53B	6.46B
Intangible Assets	485.64M	420.22M	1.35B	1.2B	1.28B	1.37B	3.82B	3.38B	3.02B	2.64B
Long-Term Investments	1.59M	0	0	0	0	24.66M	110.94M	144.62M	0	124.94M
Other Non-Current Assets	271.48M	273.07M	244.3M	270.02M	284.17M	308.38M	1.35B	166.44M	342.97M	163.45M
Total Assets+	4.17B	4.28B	6.09B	5.98B	6.54B	7.96B	15B	14.13B	13.56B	12.39B
Asset Turnover	0.51x	0.49x	0.37x	0.46x	0.44x	0.48x	0.26x	0.23x	0.20x	0.22x
Asset Growth %	0.01%	0.03%	0.42%	-0.02%	0.09%	0.22%	0.88%	-0.06%	-0.04%	-0.09%
Total Current Liabilities+	561.49M	603.36M	950.9M	771.63M	762.83M	1.65B	1.21B	1.54B	1.45B	653.1M
Accounts Payable	140.98M	168.03M	222.09M	220.95M	235.85M	327.32M	324.81M	272.83M	204.12M	167.46M
Days Payables Outstanding	43.8	53.65	66.03	52.82	54.12	66.66	76.69	64.2	52.16	42.67
Short-Term Debt	1.12M	1.17M	217.31M	14.86M	9.97M	380.95M	4.24M	470.93M	721.87M	242K
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	51.98M	58.01M	39.46M	44.69M	44.52M	47.49M	257.79M	324.85M	43.28M	44.18M
Current Ratio	1.84x	1.97x	1.26x	1.60x	1.80x	1.36x	2.01x	2.13x	2.07x	3.60x
Quick Ratio	1.38x	1.56x	0.89x	1.16x	1.33x	1.04x	1.66x	1.87x	1.77x	3.03x
Cash Conversion Cycle	108.8	98.59	127.85	111.19	119.57	149.59	91.37	98.75	141.2	134.78
Total Non-Current Liabilities+	1.49B	1.52B	2.64B	2.62B	2.96B	2.57B	6.65B	5.2B	4.24B	4.07B
Long-Term Debt	1.01B	1.05B	1.79B	1.88B	2.06B	1.61B	4.98B	3.92B	3.18B	3.15B
Capital Lease Obligations	0	0	0	0	146.4M	188.4M	147.4M	169.97M	132.75M	151.5M
Deferred Tax Liabilities	0	0	0	0	0	774.53M	1.43B	1.11B	0	0
Other Non-Current Liabilities	482.61M	474.5M	848.57M	742.31M	751.47M	0	91.7M	0	930.95M	770.52M
Total Liabilities	2.06B	2.12B	3.59B	3.39B	3.72B	4.22B	7.86B	6.75B	5.69B	4.73B
Total Debt+	1.01B	1.05B	2.01B	1.89B	2.26B	2.22B	5.16B	4.6B	4.07B	3.33B
Net Debt	774.95M	687.16M	1.8B	1.73B	2.07B	1.82B	4.56B	4.14B	3.15B	2.16B
Debt / Equity	0.48x	0.49x	0.80x	0.73x	0.80x	0.59x	0.72x	0.62x	0.52x	0.43x
Debt / EBITDA	2.72x	2.58x	4.90x	3.43x	3.64x	1.75x	3.12x	3.80x	4.89x	3.97x
Net Debt / EBITDA	2.08x	1.69x	4.40x	3.14x	3.33x	1.44x	2.76x	3.43x	3.79x	2.58x
Interest Coverage	7.02x	7.36x	6.93x	5.54x	6.37x	20.51x	13.12x	7.51x	4.04x	4.26x
Total Equity+	2.11B	2.15B	2.5B	2.58B	2.81B	3.74B	7.14B	7.38B	7.87B	7.67B
Equity Growth %	0.03%	0.02%	0.16%	0.03%	0.09%	0.33%	0.91%	0.03%	0.07%	-0.03%
Book Value per Share	18.62	19.52	22.58	23.18	25.24	33.33	61.21	58.40	63.08	62.42
Total Shareholders' Equity	2.11B	2.15B	2.5B	2.58B	2.81B	3.74B	7.14B	7.38B	7.87B	7.67B
Common Stock	112.03M	109.62M	110.36M	110.6M	111.14M	112.09M	126.24M	126.3M	123.43M	120.65M
Retained Earnings	1.99B	2.12B	2.38B	2.6B	2.81B	3.51B	4.42B	4.95B	5.61B	5.85B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-45.96M	-100.86M	-46.52M	-176.48M	-199.65M	-31.96M	-162.69M	-447.5M	-276.69M	-396.11M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	287.1M	350.62M	288.45M	311.04M	363.47M	892.18M	1.41B	679.81M	91.27M	628.3M
Operating CF Margin %	0.14%	0.17%	0.13%	0.11%	0.13%	0.24%	0.37%	0.21%	0.03%	0.23%
Operating CF Growth %	0.02%	0.22%	-0.18%	0.08%	0.17%	1.45%	0.58%	-0.52%	-0.87%	5.88%
Net Income	188.78M	215.71M	156.89M	237.47M	227.75M	630.56M	889.44M	512.68M	179.5M	283.07M
Depreciation & Amortization	105.36M	99.97M	105M	180.59M	214.03M	201.65M	311.44M	427M	431.77M	427.85M
Stock-Based Compensation	17.28M	17.16M	25.42M	28.77M	31.51M	26.9M	29.68M	51.52M	41.41M	37.81M
Deferred Taxes	-11.91M	-6.82M	29.04M	-51.77M	-61.78M	-30.82M	-53.4M	-107.41M	-97.48M	-110.31M
Other Non-Cash Items	52.53M	59.63M	9.77M	46.71M	116.61M	215.21M	100.61M	58.99M	-72.58M	8.18M
Working Capital Changes	-64.94M	-35.03M	-37.66M	-130.73M	-164.66M	-151.32M	132.99M	-262.97M	-391.35M	-18.3M
Change in Receivables	4.06M	-18.96M	-36.63M	-94.51M	-100.63M	-398.85M	165.59M	66.09M	-9M	-15.97M
Change in Inventory	-27.93M	6.75M	-17.92M	-30.18M	-9.61M	-127.36M	32.28M	-48.63M	-14.11M	45.09M
Change in Payables	-10.9M	30.72M	34.33M	8.9M	7.35M	63.23M	-7.58M	-43.8M	-76.43M	-26.02M
Cash from Investing+	-100.86M	-83.88M	-1.27B	-159.86M	-487.57M	-504.5M	-4.11B	-132.85M	1.31B	776.16M
Capital Expenditures	-28.22M	-31.7M	-39.09M	-93.25M	-81.33M	-63.63M	-86.02M	-85.63M	-81.37M	-86.65M
CapEx % of Revenue	0.01%	0.01%	0.02%	0.03%	0.03%	0.02%	0.02%	0.03%	0.03%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-598K	-1.26M	272.82M	72K	0	-13.59M	-22.96M	-15.91M	2.07B	156.9M
Cash from Financing+	-107.14M	-115.01M	782.24M	-179.23M	150.13M	-202.87M	2.94B	-661.8M	-947.12M	-1.13B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-31.57M	-30.8M	-30.79M	-31.01M	-31.06M	-31.21M	-32.37M	-35.34M	-34.97M	-34.45M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	35.94M	4.5M	-5.29M	-24.73M	-21.37M	-14.92M	-21M	-767K	-5.79M	-1.13M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	257.47M	318.91M	249.36M	217.78M	282.14M	828.54M	1.32B	594.18M	9.9M	541.65M
FCF Margin %	0.12%	0.15%	0.11%	0.08%	0.1%	0.22%	0.35%	0.18%	0%	0.2%
FCF Growth %	0.02%	0.24%	-0.22%	-0.13%	0.3%	1.94%	0.6%	-0.55%	-0.98%	53.69%
FCF per Share	2.27	2.89	2.25	1.95	2.53	7.39	11.35	4.70	0.08	4.41
FCF Conversion (FCF/Net Income)	1.35x	1.50x	2.55x	1.30x	1.60x	1.23x	1.50x	1.19x	-0.77x	2.12x
Interest Paid	31.74M	30.72M	35.78M	56.45M	82.69M	42.14M	54.12M	97.93M	94.01M	91.09M
Taxes Paid	49.27M	43.55M	77.61M	59.84M	77.06M	162.45M	364.56M	323.08M	359.8M	154.88M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	10.23%	10.96%	4.85%	9.39%	8.43%	22.23%	17.34%	7.84%	-1.55%	3.81%
Return on Invested Capital (ROIC)	6.9%	8.01%	6.39%	6.45%	6.62%	14.66%	11.65%	5.05%	2.66%	2.95%
Gross Margin	44.19%	45.96%	45.61%	45.04%	44.84%	52.62%	59.62%	53.16%	48.07%	48.01%
Net Margin	10.09%	11.05%	5.01%	8.6%	7.89%	19.25%	24.64%	17.19%	-4.3%	10.74%
Debt / Equity	0.48x	0.49x	0.80x	0.73x	0.80x	0.59x	0.72x	0.62x	0.52x	0.43x
Interest Coverage	7.02x	7.36x	6.93x	5.54x	6.37x	20.51x	13.12x	7.51x	4.04x	4.26x
FCF Conversion	1.35x	1.50x	2.55x	1.30x	1.60x	1.23x	1.50x	1.19x	-0.77x	2.12x
Revenue Growth	-5.92%	0.51%	6.69%	23.08%	3.8%	31.18%	1.19%	-13.48%	-16.95%	0.16%

Revenue by Segment

	2024
Diagnostics	1.5B
Diagnostics Growth	-
Life Sciences	1.25B
Life Sciences Growth	-

Revenue by Geography

	2024
Other International	2.75B
Other International Growth	-
UNITED STATES	1.1B
UNITED STATES Growth	-
CHINA	450.01M
CHINA Growth	-
UNITED KINGDOM	112.88M
UNITED KINGDOM Growth	-

Frequently Asked Questions

Valuation & Price

Revvity, Inc. (RVTY) has a price-to-earnings (P/E) ratio of 47.9x. This suggests investors expect higher future growth.

Growth & Financials

Revvity, Inc. (RVTY) reported $2.81B in revenue for fiscal year 2024. This represents a 46% increase from $1.92B in 2011.

Revvity, Inc. (RVTY) grew revenue by 0.2% over the past year. Growth has been modest.

Yes, Revvity, Inc. (RVTY) is profitable, generating $238.3M in net income for fiscal year 2024 (10.7% net margin).

Dividend & Returns

Yes, Revvity, Inc. (RVTY) pays a dividend with a yield of 0.24%. This makes it attractive for income-focused investors.

Revvity, Inc. (RVTY) has a return on equity (ROE) of 3.8%. This is below average, suggesting room for improvement.

Revvity, Inc. (RVTY) generated $497.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...